All In Biotech

Drug Trial Radar · NCT01035255

This Study Will Evaluate the Efficacy and Safety of LCZ696 Compared to Enalapril on Morbidity and Mortality of Patients With Chronic Heart Failure

A Multicenter, Randomized, Double-blind, Parallel Group, Active-controlled Study to Evaluate the Efficacy and Safety of LCZ696 Compared to Enalapril on Morbidity and Mortality in Patients With Chronic Heart Failure and Reduced Ejection Fraction

Last checked: Nov 19, 2026Latest source record: Aug 15, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingPhase 3. Randomized with 8,442 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

8,442

Actual

Start

Dec 2009

Primary completion

May 2014

Study completion May 2014

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Dec 18, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study will evaluate the efficacy and safety of LCZ696 compared to enalapril on morbidity and mortality in patients with chronic heart failure (NYHA Class II - IV and EF =\< 35%).

Conditions

  • Heart Failure With Reduced Ejection Fraction

Interventions

  • LCZ696 200 mg BIDDrug

    LCZ696 200 mg BID

  • Enalapril 10 mg BIDDrug

    Enalapril 10 mg BID

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants That Had First Occurrence of the Composite Endpoint, Which is Defined as Either Cardiovascular (CV) Death or Heart Failure (HF) HospitalizationTime frame: up to 51 months

Locations

1,031 sites in 47 countries. Site status is shown where the registry gives one.

  • Novartis Investigative Site

    Birmingham, Alabama

  • Novartis Investigative Site

    Birmingham, Alabama

  • Novartis Investigative Site

    Huntsville, Alabama

  • Novartis Investigative Site

    Mobile, Alabama

  • Novartis Investigative Site

    Muscle Shoals, Alabama

  • Novartis Investigative Site

    Anchorage, Alaska

  • Novartis Investigative Site

    Gilbert, Arizona

  • Novartis Investigative Site

    Phoenix, Arizona

  • Novartis Investigative Site

    Phoenix, Arizona

  • Novartis Investigative Site

    Little Rock, Arkansas

  • Novartis Investigative Site

    Little Rock, Arkansas

  • Novartis Investigative Site

    Anaheim, California

  • Novartis Investigative Site

    Bellflower, California

  • Novartis Investigative Site

    Berkley, California

  • Novartis Investigative Site

    Loma Linda, California

  • Novartis Investigative Site

    Los Angeles, California

  • Novartis Investigative Site

    Los Angeles, California

  • Novartis Investigative Site

    Mather, California

  • Novartis Investigative Site

    Oceanside, California

  • Novartis Investigative Site

    Palm Springs, California

  • Novartis Investigative Site

    Pomona, California

  • Novartis Investigative Site

    Sacramento, California

  • Novartis Investigative Site

    San Diego, California

  • Novartis Investigative Site

    San Diego, California

  • Novartis Investigative Site

    Santa Rosa, California

  • Novartis Investigative Site

    Stockton, California

  • Novartis Investigative Site

    Tustin, California

  • Novartis Investigative Site

    Denver, Colorado

  • Novartis Investigative Site

    Denver, Colorado

  • Novartis Investigative Site

    Stamford, Connecticut

  • Novartis Investigative Site

    Washington D.C., District of Columbia

  • Novartis Investigative Site

    Boynton Beach, Florida

  • Novartis Investigative Site

    Davie, Florida

  • Novartis Investigative Site

    Fort Lauderdale, Florida

  • Novartis Investigative Site

    Gainesville, Florida

  • Novartis Investigative Site

    Jacksonville, Florida

  • Novartis Investigative Site

    Jacksonville, Florida

  • Novartis Investigative Site

    Jacksonville, Florida

  • Novartis Investigative Site

    Lakeland, Florida

  • Novartis Investigative Site

    Leesburg, Florida

Showing 40 of 1,031 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.